BioMarin's Strategic $4.8B Acquisition Boosts Rare Disease Leadership

BioMarin Pharmaceutical shares are trading higher after announcing its $4.8 billion acquisition of Amicus Therapeutics, enhancing its position in rare diseases and accelerating revenue growth.